ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Organ Systems Program Adds Workshops On Lung, Colorectal Cancer

January 26, 1990

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

DO RFAs cut Into R01 Grant Pool? Board Asks

July 2, 1999

Scientists, Public Citizen Urge FDA To Ban Sale Of Obesity Drug Orlistat.

June 2, 2006

Clinical Trials Issues: Maryland Law Mandates Insurance Coverage Of Patient Care Costs In Clinical Trials

July 3, 1998

In Brief: Lee Helman To Head NCI Pediatric Branch; HHS to Hear From Academic Health Centers

August 22, 1997